Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 20Prostatic Neoplasms 19Glioblastoma 18Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 12Rectal Neoplasms 11Oropharyngeal Neoplasms 10Neoplasms 9Head and Neck Neoplasms 8Glioma 8Astrocytoma 8Neoplasm Metastasis 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Squamous Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Hodgkin Disease 5Gliosarcoma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Burkitt Lymphoma 5Brain Neoplasms 5Adenocarcinoma of Lung 5Adenocarcinoma Of Esophagus 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

atezolizumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1Radiotherapy 1Radiation 1LB100 1Etoposide 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Radiotherapy × 90 days × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡